Editas Medicine (EDIT) Common Equity (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Common Equity data on file, last reported at $27.3 million in Q4 2025.

• Quarterly Common Equity fell 79.68% year-over-year to $27.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.3 million (down 79.68% YoY) and the FY2025 annual result came in at $27.3 million, down 79.68% from the prior year.
• Common Equity climbed to $27.3 million in Q4 2025 per EDIT's latest filing, from $13.5 million in the prior quarter.
• Across five years, Common Equity topped out at $638.0 million in Q1 2021 and bottomed at $13.5 million in Q3 2025.
• The 5-year median for Common Equity is $354.8 million (2023), against an average of $326.6 million.
• The widest annual swing landed in 2021, when Common Equity surged 171.99%; it then slumped 92.34% in 2025.
• Tracing EDIT's Common Equity over 5 years: stood at $553.6 million in 2021, then plunged by 34.85% to $360.7 million in 2022, then slipped by 3.21% to $349.1 million in 2023, then slumped by 61.54% to $134.3 million in 2024, then sank by 79.68% to $27.3 million in 2025.
• Per Business Quant, the three latest EDIT Common Equity figures stand at $27.3 million (Q4 2025), $13.5 million (Q3 2025), and $19.2 million (Q2 2025).

Peer Comparison